健康元药业集团股份有限公司2026年第一季度报告(英文版)

Joincare Pharmaceutical Group Industry Co., Ltd. 2026 First Quarterly Report 1 / 12 Stock Code: 600380 Stock Short Name: 健康元 Joincare Pharmaceutical Group Industry Co., Ltd. 2026 First Quarterly Report The Board of Directors and all Directors of the Company hereby warrant that there are no false representations, misleading statements or material omissions contained in this announcement and accept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof. IMPORTANT NOTICE:  The Board of Directors, directors, and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this quarterly report, and that there are no false representations, misleading statements or material omissions contained herein, and severally and jointly accept legal responsibility.  The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.  Whether the first quarterly financial statements have been audited. □Yes √No I. MAJOR FINANCIAL DATA (I) Major Accounting Data and Financial Indicators Unit: Yuan Currency: RMB Item The Reporting Period (From January to March) The same period of the previous year YoY change (%) Revenues 3,721,497,528.96 4,089,279,479.56 -8.99 Total profit 1,036,837,891.56 1,151,118,552.69 -9.93 Net profit attributable to shareholders of the listed company 414,971,222.32 435,788,328.07 -4.78 Net profit attributable to shareholders of the listed company after deduction of extraordinary gains and losses 406,044,025.41 423,759,792.88 -4.18 Joincare Pharmaceutical Group Industry Co., Ltd. 2026 First Quarterly Report 2 / 12 Net cash flow from operating activities 914,648,142.82 809,939,509.20 12.93 Basic earnings per share (RMB/share) 0.23 0.23 - Diluted earnings per share (RMB/share) 0.23 0.23 - Weighted average return on net assets (%) 2.70 2.99 Decreased by 0.29 percentage points As at the end of the Reporting Period As at the end of the previous year Change as at the end of the Reporting Period as compared to the end of the previous year(%) Total assets 35,477,298,744.83 35,414,299,308.64 0.18 Owner's equity attributable to shareholders of the listed company 15,610,934,233.56 15,179,567,286.42 2.84 (II) Items and Amounts of Extraordinary Gains and Losses √Applicable □N/A Unit: Yuan Currency: RMB Item For the Reporting Period Explanations Gains and losses on disposal of non-current assets (including the reversal of previously recognized asset impairment provisions) 8,700,507.66 Gain or Loss on disposal of non-current assets Government grants recognized in profit or loss for the current period (excluding government grants that

立即下载
综合
2026-04-25
12页
0.34M
收藏
分享

健康元药业集团股份有限公司2026年第一季度报告(英文版),点击即可下载。报告格式为PDF,大小0.34M,页数12页,欢迎下载。

本报告共12页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共12页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
国泰海通财务预测表
综合
2026-04-25
来源:2026年一季报点评:扣非净利润同比+73%,经纪、投行等市场份额提升显著:国
查看原文
国泰海通 2020-2026Q1 收入结构
综合
2026-04-25
来源:2026年一季报点评:扣非净利润同比+73%,经纪、投行等市场份额提升显著:国
查看原文
国泰海通 2020-2026Q1 扣非净利润
综合
2026-04-25
来源:2026年一季报点评:扣非净利润同比+73%,经纪、投行等市场份额提升显著:国
查看原文
国泰海通 2020-2026Q1 营业收入
综合
2026-04-25
来源:2026年一季报点评:扣非净利润同比+73%,经纪、投行等市场份额提升显著:国
查看原文
2025-2035 年不同电池技术路线市场占比变化趋势
综合
2026-04-25
来源:2025年年度报告
查看原文
2011-2025 年我国光伏新增装机情况(单位:GW)
综合
2026-04-25
来源:2025年年度报告
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起